Top Markets
Coin of the day
Mabion S.A. Mabion S.A.

Mabion S.A.

MAB
Rank in Stocks #27034
Mabion S.A. is a Polish biopharmaceutical firm dedicated to pioneering the... Mabion S.A. is a Polish biopharmaceutical firm dedicated to pioneering the development of biological drugs, primarily leveraging monoclonal antibody technology. The company oversees the full spectrum from research and development to the manufacturing and commercialization of therapies designed to combat a wide range of diseases, including neoplastic (cancer), autoimmune, metabolic, and neurological disorders. Key products in its portfolio include MabionCD20 and MabionHER2. Established in 2007, Mabion S.A. maintains its headquarters in Konstantynรณw Lรณdzki, Poland.
Share Price
$2.19
Market Cap
$35.44M
Change (1 day)
1.96%
Change (1 year)
-16.03%
Country
PL
Trade Mabion S.A. (MAB)

Category

P/B ratio for Mabion S.A. (MAB)
P/B ratio as of 2026 TTM: 0
According to Mabion S.A. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Mabion S.A. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
3.7087 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH